Novo Nordisk AS ADR NVO

Stock XNYS Rating as of Jul 14, 2026

$49.07 −0.21 (0.43%)

View Full Chart

As of Jul 14, 2026, 8:00:15 PM Delayed Price Pre-Open: $49.02 −0.04

Company Report

View Archive

Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat

Karen Andersen Feb 23, 2026

A pioneer in diabetes care, Novo Nordisk has been in the business for over 85 years. It claims 30% of the $100 billion diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in the coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to innovate in both diabetes and obesity therapies.

Read Full Report

Price vs Fair Value

View History

NVO is trading at a LOCK|Vb<RWwd premium.

Price

$49.07

Jul 14, 2026

Fair Value

Feb 23, 2026

Uncertainty

LOCK|$r

1-Star Price: LOCK|.>$
5-Star Price: LOCK|.%x
Economic Moat: LOCK|Fz
Capital Allocation: LOCK|<<?r?mLJ

Bulls Say, Bears Say

Bulls

Novo's Wegovy and Wegovy pill are expanding the obesity treatment market with strong efficacy and convenience, and are poised to remain key drugs until patent expiration in 2032.

Bears

Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from US pricing pressure due to competition from Sanofi and Lilly, and biosimilar insulins have weighed on category pricing since 2017.

News

View All

Articles & Videos

Trading Information

Previous Close Price: $49.28
Day Range: $48.29–49.27
52-Week Range: $35.12–71.80
Bid/Ask: $49.01 / $49.04
Shares Outstanding: 4.42B
Market Cap: $217.08B
Volume/Avg: 53,245 / 14M

Key Statistics

Price/Earnings (Normalized): 12.17
Price/Sales: 4.29
Dividend Yield (Trailing): 3.67%
Dividend Yield (Forward): 3.67%
Total Yield: 3.84%

Company Profile

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Sector: Healthcare
Industry: Drug Manufacturers - General
Stock Style Box: Large Core
Total Number of Employees: 68,794
Website: https://www.novonordisk.com

Competitors

Valuation

Metric	NVO	LLY	RHHBY
Price/Earnings (Normalized)	12.17	39.18	15.77
Price/Book Value	6.99	33.01	7.48
Price/Sales	4.29	14.33	4.23
Price/Cash Flow	10.68	38.52	13.86

Price/Earnings

NVO

LLY

RHHBY

Financial Strength

Metric	NVO	LLY	RHHBY
Quick Ratio	0.54	0.72	1.10
Current Ratio	0.79	1.50	1.38
Interest Coverage	—	—	13.46

Quick Ratio

NVO

LLY

RHHBY

Profitability

Metric	NVO	LLY	RHHBY
Return on Assets (Normalized)	22.35%	24.73%	15.77%
Return on Equity (Normalized)	66.15%	114.33%	49.73%
Return on Invested Capital (Normalized)	37.39%	40.96%	23.68%

Return on Assets

NVO

LLY

RHHBY

Drug Manufacturers - General Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Eli Lilly and Co LLY	LOCK\|rN^WH!&	LOCK\|Ql	$1T
Johnson & Johnson JNJ	LOCK\|gR>MTv	LOCK\|^T!	$611B
AbbVie Inc ABBV	LOCK\|lf$V?@q	LOCK\|^%	$432B
Roche Holding AG ADR RHHBY	LOCK\|h^%$%kH	LOCK\|jy	$320B
Merck & Co Inc MRK	LOCK\|TN#%P!z	LOCK\|gZD	$298B
Novartis AG ADR NVS	LOCK\|cymQ>@WZ	LOCK\|!Gh	$287B
AstraZeneca PLC AZN	LOCK\|w<<!Hzw>	LOCK\|@s>	$256B
Amgen Inc AMGN	LOCK\|>F>D^@#	LOCK\|?bw	$192B
Gilead Sciences Inc GILD	LOCK\|@^dDk$^	LOCK\|hw	$161B

Novo Nordisk AS ADR NVO

Company Report

Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat

Price vs Fair Value

Bulls Say, Bears Say

Bulls

Bears

News

One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

It can take as little as 5 minutes online to get prescribed a GLP-1 for weight loss. Why that's risky.

A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It

Millions of Americans can get Medicare to cover GLP-1s for weight loss starting this week. Here's how much it costs.

Canada Approves Apotex's Bid to Sell Generic Version of Wegovy

Older Americans will soon have Medicare access to GLP-1s for weight loss for the first time. Here's what they need to know.

How Micron aims to break through the risk cycle that has spooked investors for decades

Novo Nordisk's Wegovy Pill Gains U.K. Approval, Its First in Europe — Update

Articles & Videos

As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus

Why We Rate American Funds New Perspective Highly

The Best Healthcare Stocks to Buy

Hims & Hers: Repartnering With Novo Removes Legal Overhang and Reshapes Weight Loss Segment

Weekly Market Update: Stocks Edge Lower as Consumer Defensives Rise and Financial Services Fall

Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy

34 New 4-Star Stocks This Week

Markets Brief: What’s Clipping Microsoft Stock, Pharma Earnings and Jobs Report on Deck

Eli Lilly vs. Novo Nordisk: Which Is the Best Stock to Buy Today?

Trading Information

Key Statistics

Company Profile

Competitors

Valuation

Financial Strength

Profitability

Drug Manufacturers - General Industry Comparables

Sponsor Center

What We Do

Company

Get Help